A first-half review of biotech and biopharma acquisitions announced between 1 January and 30 June 2026 — covering deal value, structure, therapeutic area, acquirer behaviour, and what the tape is signalling about where strategic capital is flowing.
The half closed with 49 control transactions and ~$149B in disclosed value. Activity accelerated sharply — Q2 nearly doubled Q1’s deal count and delivered more than twice its value. Oncology led by volume, immunology led by strategic intent, and Eli Lilly outbought everyone with 11 deals spanning almost every modality.
Value stayed highly concentrated: 11 deals of ≥$5B accounted for ~$97B — roughly two-thirds of all disclosed value from just over a fifth of the transactions.
January opened slowly ($4.6B / 4 deals). Pace built through Q1 and stayed elevated across Q2, peaking in June at ~$42B — the busiest month of the half by value, carried by three ~$10B+ takeouts on the tools and pipeline side.
Count and value diverge sharply. Specialty pharma is only 2 deals but ranks third by dollars — the two commercial take-privates, Recordati (~$12.4B) and Organon (~$11.75B). Platforms & tools is carried almost entirely by one deal(Bio-Techne = $11.3B of $14.8B). Neuroscience is deep by count (7) but mid-table by dollars; respiratory and cardiometabolic were quiet on both. “Rare & other” (shown last) is the residual — Soleno (PWS) and Vega (VWD), both rare, plus Perfuse (retinal).
Rare disease doesn’t sit in one bucket — it’s scattered across the report. Counting deals with a primary orphan indication gives ~9 deals / ~$24B, spanning immunology (KalVista/HAE, Apellis/PNH-C3G), neuroscience (Catalyst/LEMS, Edgewise/muscular dystrophy, Neurona/epilepsy), oncology (Day One/pediatric glioma), respiratory (35Pharma/PH) and specialty (Soleno/PWS, Vega/VWD).
Lilly is in a category of its own — 11 deals and ~$25B, more than 1-in-5 transactions market-wide. Gilead ($15B / 3) and GSK ($13.8B / 3) are the other serial buyers; the tier below is mostly single mega-deals (AbbVie / Apogee, Merck / Terns). Chart shows R&D-driven (innovative) pharma acquirers only — excluded here and captured in the full tracker are the two largest commercial tickets, CVC-GBL / Recordati (financial sponsor) and Sun Pharma / Organon (generics-led), plus Merck KGaA / Bio-Techne ($11.3B, a life-science tools deal). Values include contingent milestones.
Range from a 4% discount (Theravance) to ~140%, median ~36% but mean ~39%— the gap is the Apellis outlier (~140% off a depressed base) pulling the average up. Bubble size is deal value: the biggest bubbles (Recordati, Organon, Bio-Techne) cluster at low premiums (~13–24%) — large, de-risked or commercial assets don’t need fat premiums, while the richest premiums went to smaller, beaten-down or contested names (RAPT, Arcellx, Day One, Apellis). Premiums quoted to prior close unless the deal is best known on a VWAP basis.
Deal count doubled from 16 in Q1 to 33 in Q2, and disclosed value jumped from ~$44B to ~$105B. Rather than the usual summer fade, June was the single biggest month of the half (~$42B) on the back of three separate $10B-plus takeouts — Bio-Techne, Apogee, and Nuvalent. All five of H1's ≥$10B deals landed in Q2. The tape exited the half with momentum, not exhaustion.
Oncology was the single busiest area (14 deals, ~$46B), spanning ADCs (Tubulis, CrossBridge, Firefly), cell therapy (Kelonia, Arcellx, InnocsAI) and targeted small molecules (Nuvalent, Terns, Ajax, Kartos). But immunology & inflammation (10 deals, ~$32B) is where the platform conviction concentrates — anti-IgE (RAPT, Excellergy), complement (Apellis), oral inflammation/NLRP3 (Ventyx), and the immune-reset wave. Together the two areas are half of all deals and just over half of all disclosed value.
BCMA×CD3 T-cell engagers and in vivo CAR-T built for oncology are being acquired explicitly to reset the immune system in autoimmune disease — Gilead/Ouro, UCB/Candid, and Lilly/Orna. Buyers are paying upfront for the bet that oncology-grade depth of B-cell depletion converts into durable, drug-free autoimmune remission. This is arguably the defining immunology theme of the half.
Eli Lilly signed 11 of 49 deals (~$25B disclosed) — more than one in five transactions across the entire market, and ~17% of all capital deployed. Its footprint spans oral inflammation (Ventyx), in vivo cell therapy (Orna, Kelonia), CNS (Centessa), non-opioid pain (4E), ADCs (CrossBridge), genetic-medicine delivery (Engage) and a three-shot vaccine spree in a single May day (Curevo, Vaccine Company, LimmaTech). It is converting incretin cash flow into optionality across nearly every modality.
GSK did its largest deal in over a decade (Nuvalent, $10.6B) to rebuild oncology scale ahead of dolutegravir LOE; AbbVie deepened immunology beyond the Skyrizi/Rinvoq/Humira franchise (Apogee, $10.9B); Biogen kept pivoting out of legacy neurology into immunology (Apellis, then RayThera); and Merck kept feeding its post-Keytruda pipeline (Terns). Loss-of-exclusivity math is visibly steering deal selection at the large-cap end.
Enabling-infrastructure deals were a genuine lane this half — headlined by Merck KGaA's $11.3B Bio-Techne tools takeout, plus Roche/PathAI (digital pathology + AI diagnostics), Halozyme/Surf Bio and Lilly/Engage (delivery), Amneal/Kashiv (biosimilar manufacturing) and Ligand/XOMA (royalty aggregation). Strategics are increasingly paying for the tools, delivery, data and financing layers that sit around the molecule, not just the molecule itself.
The two largest headline tickets of the half were not pipeline takeouts at all: CVC/GBL's ~$12.4B Recordati take-private and Sun Pharma's ~$11.75B Organon acquisition. Add ARCHIMED/Esperion and Angelini/Catalyst and a clear pattern emerges — durable commercial platforms are being bought for operating control and cash flow, frequently by financial sponsors or ex-US buyers seeking a US beachhead rather than a single R&D asset.
31 of 49 targets were private (63% of deals) but just ~31% of disclosed value; the 18 public deals delivered ~69% of the dollars, averaging ~$5.7B versus ~$1.5B private. Public-deal premiums ranged from a ~4% discount (Theravance, a strategic-alternatives sale) to ~140% (Apellis, off a depressed base), with a median around ~36%. Low-premium deals (Ventyx +2%, Terns +6%, Recordati +13%) reflect pre-deal re-rating or take-private mechanics; CVRs (Apellis, Arcellx, Centessa, Theravance) remain the tool of choice to bridge milestone-dependent value.
